Cogent Biosciences, Inc.
Key Metrics
Market Snapshot
About
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, particularly advanced systemic mastocytosis and other mast cell-related conditions. Headquartered in Waltham, Massachusetts, the company's lead product candidate is bezuclastinib, an oral tyrosine kinase inhibitor designed to inhibit KIT D816V, a mutation found in most patients with systemic mastocytosis. Cogent utilizes a precision medicine approach to identify and treat patients with specific genetic mutations. The company is advancing clinical development programs for both hematologic and solid tumor indications.